Lupin receives tentative USFDA approval for its generic HIV treatment, combining Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide. The drug, equivalent to Janssen's Symtuza, has ...

One cupcake won't kill you,' 'I'm going to get diabetes just looking at that,' 'That person doesn't look like they ...

IQVIA , a leading global provider of clinical research services, commercial insights and healthcare intelligence, was named No. 1 in its category on the 2025 Fortune® World's Most Admired Companiestm ...

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, was named No. 1 in its category on the 2025 Fortune® World’s Most Admired ...

Makers of drugs and medical devices say the tariffs on goods from Canada, Mexico and China could have an outsized impact on ...

The company has received tentative approval from the US Food and Drug Administration (USFDA) for Darunavir, Cobicistat, ...

JB Pharma on Tuesday reported a 22% year-on-year (Y-o-Y) jump in net profit to Rs 162 crore for the quarter ended December 31 ...

The portfolio’s return was -3.87% (net) for the reporting period vs. MSCI World Index that returned -0.16% for the same ...

DeepSeek massively disrupted the artificial intelligence story. All after DeepSeek “presented a ChatGPT-like model called R1, ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Let's sort the S&P 500 healthcare sector again to show the 10 stocks with the highest percentages of "buy" or equivalent ratings. Only five companies are on both this list and the above growth list: ...

Bavarian Nordic’s stock dropped around 10% on the Danish stock exchange Tuesday after reporting disappointing 2024 sales ...